NY-ESTÉE-LAUDER
23.7.2024 23:01:30 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) (“ELC” or “the Company”) today announced that Akhil Shrivastava has been appointed Executive Vice President and Chief Financial Officer, succeeding Tracey T. Travis, whose intention to retire was announced on July 11, 2024. Akhil will report to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer, consistent with the reporting structure for Tracey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723453390/en/
The Estée Lauder Companies Names Akhil Shrivastava as Executive Vice President and Chief Financial Officer, Effective November 1, 2024 (Photo: Business Wire)
Akhil will assume his new role effective November 1, 2024. Tracey will remain at the Company until her retirement on June 30, 2025 to support a seamless transition.
“With over 25 years of extensive financial and leadership experience, Akhil is an exceptional and capable leader whose financial and strategic expertise and insights have been important in supporting the Company over the past several years, and he will be instrumental in driving forward our strategic direction and decisions,” said Fabrizio Freda. “I look forward to partnering with Akhil as we continue to rebuild stronger, more sustainable profitability and sales growth acceleration across the business.”
In his new role as Chief Financial Officer, Akhil will be responsible for the Company’s Global Finance, Accounting, Tax, Treasury, Investor Relations and New Business Development organizations. He will lead ELC’s Global Finance & Strategy (F&S) organization and will continue to cultivate and strengthen the tremendously talented Finance & Strategy Team, continuing to imbue agility and consumer-focus across the organization to drive sustainable value creation, governance, and strategic business objectives and priorities for the long-term.
Since joining ELC in 2015, Akhil has held several senior finance roles within the Company. He was recently named ELC’s Senior Vice President, Corporate Controller, a role that oversees Corporate Accounting and Financial Planning & Analysis, the International and Online Finance organizations, Pricing and Value Chain Finance, serving on both the Finance & Strategy Leadership Team and Executive Leadership Team. He also oversees the Operational Excellence pillar as part of the Profit Recovery and Growth Plan focused on driving strong inventory, cash, and cost improvements for the Company. Prior to his current role, he was Senior Vice President, Treasurer, where he was responsible for core Treasury functions, the Enterprise Risk Program, Real Estate, and oversight of the Company’s retirement funds.
Akhil will serve as a member of several of ELC’s senior management leadership groups including the Executive Leadership Team, Investment Development Committee, Fiduciary Investment Committee, and Corporate Risk Management Committee. In some cases, his membership will continue, and, in others, he will be a new member.
“Akhil has demonstrated his capabilities as a transformational, visionary, and collaborative leader who combines finance and strategy with an appreciation for the creativity within our business and our brands with consumers at the heart,” said William P. Lauder. “He also has a keen ability to cultivate high-performing teams and organizations and will continue to strengthen the tremendously talented Finance & Strategy organization, which will be instrumental in continuing to drive our strategic business objectives and priorities for the long-term.”
Akhil first joined ELC in 2015 as Vice President, Global Finance & Strategy for the Estée Lauder brand and was then appointed to the role of Senior Vice President, Global Finance & Strategy for Jane Hertzmark Hudis’ Brand Cluster in January 2019, where he provided strategic leadership and financial guidance while maximizing business and transformational opportunities across the brand cluster. Specifically, he helped allocate resources to support and promote the best growth opportunities from a consumer, sub-category, geography, and channel perspective.
He has also served as a valued member of many key enterprise initiatives at the Company, providing strategic financial direction for projects which include transforming ELC’s planning processes and capabilities to support the end-to-end business from consumer demand to delivery.
“With its leading portfolio of iconic brands, extensive global reach, and impressively talented people, I am honored to lead the Global Finance team,” said Akhil Shrivastava. “I look forward to helping to advance the Company’s multiple engines of growth to rebuild stronger, more sustainable profitability and support sales growth acceleration across brands, product categories, and regions while evolving the business for the future.”
Before joining The Estée Lauder Companies, Akhil spent eighteen years at Procter & Gamble, where he served in several finance and leadership roles across Asia, North America, and the global businesses, including Finance Director for Gillette, North America.
Akhil is a graduate of Engineering College in Rewa, India and has a Master’s Degree in Finance and Control from Delhi University.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include the various quotations related to rebuilding profitability and sales growth and the future of the finance and strategy function. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s profit recovery and growth plan and those described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2023. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723453390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
